Evidence concludes that BRAF/KRAS mutations can also be present in benign ovarian tumours as well as in serous and mucinous BOTs; this supports the hypothesis that such mutations are early features in the low-grade serous carcinoma pathway, potentially representing more favourable prognosis in that setting [38]. This evidence concerns the gene KRAS and serous adenocarcinoma.